Bicycle Therapeutics Appoints Andy Sandham as Non-Executive Chairman

CAMBRIDGE, England--(BUSINESS WIRE)-- Bicycle Therapeutics today announced the appointment of Andy Sandham as non-executive Chairman. Andy brings over 30 years experience in building biotechnology businesses. He will work closely with founders, Sir Gregory Winter, FRS and Christian Heinis, and CEO, Dr John Tite, to drive the discovery and development of a new generation of biotherapeutics using the company’s proprietary bicyclic peptide technology. In addition to Andy’s appointment, Bruce Booth will be joining the Board to replace Regina Hodits as the Atlas Venture representative director.

Andy Sandham has played a key role in building successful businesses in pharmaceutical discovery and development in Europe and the USA, serving as a founder and executive of Cantab Pharmaceuticals, Hexagen, Signature BioScience and Ionix Pharmaceuticals. He has also served as non-executive chairman of Syntaxin, Novacta Biosystems, non-executive director of Synosia and was a venture partner with Abingworth LLP. Andy is currently also Chairman and CEO of Kymab and is a non-executive director of NeurAxon and PBL.

"We are delighted to welcome Andy as our chairman. Andy has a wealth of experience in the biotechnology arena that will be invaluable as we look to continue to build our business. I would also like to thank Regina Hodits for the major contribution that she has made to the initial development of the company and we look forward to working with Bruce on the Board of Directors," said John Tite.

Andy Sandham said, "Bicycle has an extraordinary technology platform that has the potential to combine the proven benefits of therapeutic antibodies with the attractive features and manufacturing simplicity of small molecules. I am very excited to be working with Greg Winter, John Tite and the board as we enter the drug discovery and pharma partnering stage of our corporate development."

About Bicycle Therapeutics

Bicycle Therapeutics is a biotechnology company based at the Babraham Research Campus in Cambridge, U.K. developing a novel technology for the creation of a new generation of biotherapeutics which combine the desirable features of small molecules and biopharmaceuticals. Bicycle technology is based on the work performed at the MRC Laboratory of Molecular Biology in Cambridge by the scientific founders of the company, Prof. Christian Heinis and Sir Gregory Winter and is managed by Dr John Tite (CEO). The company was founded in July 2009 and is funded by Atlas Venture, Novartis Venture Fund, SVLS and SR One. For more information visit www.bicycletherapeutics.com



CONTACT:

Bicycle Therapeutics Limited
John Tite
Phone: +44 (0)1223 497390
Mobile: +44 (0)7798 791337

[email protected]
Web-site: http://www.bicycletherapeutics.com

KEYWORDS:   United Kingdom  United States  Europe  North America  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Research  Other Science  Science

MEDIA:

Logo
 Logo

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.